Osteonecrosis due to drugs, left shoulder
ICD-10 M87.112 is a billable code used to indicate a diagnosis of osteonecrosis due to drugs, left shoulder.
Osteonecrosis, also known as avascular necrosis, is a condition characterized by the death of bone tissue due to a lack of blood supply. In the case of M87.112, the osteonecrosis is specifically attributed to the use of certain medications, which can disrupt blood flow to the bone. This condition often affects the femoral head but can also occur in other joints, including the shoulder. The left shoulder is particularly susceptible to osteonecrosis due to its anatomical structure and the vascular supply to the humeral head. Patients may present with pain, limited range of motion, and functional impairment. Diagnosis typically involves imaging studies such as X-rays or MRI to assess the extent of bone damage. Treatment options may include conservative management, such as physical therapy and pain relief, or surgical interventions like core decompression or joint replacement, depending on the severity of the condition. Understanding the underlying causes, including drug-induced factors, is crucial for effective management and coding.
Detailed history of medication use, imaging results, and treatment plans.
Patients presenting with shoulder pain and a history of corticosteroid use.
Ensure that the documentation clearly links the drug use to the osteonecrosis diagnosis.
Comprehensive medication history, including duration and dosage of drugs that may cause osteonecrosis.
Patients with autoimmune disorders on long-term immunosuppressive therapy.
Consideration of other comorbidities that may affect bone health.
Used in cases where surgical intervention is required for osteonecrosis.
Operative report detailing the procedure and findings.
Orthopedic documentation must clearly outline the necessity for surgery.
Common medications include corticosteroids, bisphosphonates, and certain chemotherapy agents. It is important to document the specific medication and dosage when coding.